- Member Services
- Patient Safety
|Contrast Medium FactFinder|
Committed to providing helpful information to International Spine Intervention Society members about key patient safety issues, the Patient Safety Committee has developed a FactFinder series. FactFinders will explore and debunk myths surrounding patient safety issues. The intent of this FactFinder is to clarify the different indications for use of different formulations of contrast medium and the reported adverse effects related to each.
Myth: Isovue and Isovue-M have the same indications.
Fact: The indications for Isovue and Isovue-M overlap, but are still unique. Isovue is not indicated for intrathecal use, while Isovue-M is specifically indicated for intrathecal use.
When contrast medium is used for spinal injections, intrathecal injection of contrast or steroids is not expected. As articulated in the International Spine Intervention Society FactFinder on Preservatives,1 if the needle tip is properly placed, intrathecal injection of contrast medium is unlikely and therefore the choice of Isovue or Isovue-M is inconsequential.
For intrathecal pumps and intrathecal neurolysis, or when inadvertent intrathecal injection of contrast medium is a concern, the correct choice of contrast medium is necessary. The different indications for Isovue and Isovue-M are clearly defined in the package inserts.
If used in the nervous system there is a clear risk of adverse reactions including pain (2.8%) and burning sensation (1.4%).2
There have been no central nervous system adverse reactions with an incidence greater than 1% when Isovue-M was injected.3
Myth: Omnipaque 350 and Omnipaque 300 have the same indications.
Fact: The indications for Omnipaque 300 and Omnipaque 350 overlap, but are still unique. Omnipaque 350 is not indicated for intrathecal use, while Omnipaque 300 is specifically indicated for intrathecal use.
The different indications for Omnipaque 300 and Omnipaque 350 are clearly defined on the packaging and in the package inserts.
been no central nervous system adverse reactions with an incidence greater than
1% when Omnipaque 300 was injected.5
10/21/2016 » 10/23/2016
European Congress - Lisbon, Portugal
11/11/2016 » 11/13/2016
Advanced Cervical Bio-Skills Lab - Long Beach, CA
1/13/2017 » 1/15/2017
Radiofrequency Bio-Skills Lab - Long Beach, CA
1/27/2017 » 1/29/2017
Evidence-Based Spine Interventions Seminar - Palm Springs, CA
Inaugural SIS Golf Tournament
2/10/2017 » 2/12/2017
Lumbar Bio-Skills Lab - Phoenix, AZ